SCHEMBL14308

SCHEMBL14308

NCCCCCN1CC=C(n2cc3cc(-c4ccc(F)cc4)[nH]c3nc2=O)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.39
KCNH2 Q12809 2/20 0.37
SIGMAR1 Q99720 1/20 0.37
PARP2 Q9UGN5 1/20 0.37
HRH4 Q9H3N8 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
CACNA1F O60840 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
CHRM4 P08173 1/20 0.36
CYP3A4 P08684 1/20 0.36
CHRM5 P08912 1/20 0.36
ADRA2A P08913 1/20 0.36
CYP2D6 P10635 1/20 0.36
MAPT P10636 1/20 0.36
CYP2C9 P11712 1/20 0.36
DRD2 P14416 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13994 0.99 PARP1 (0.39) PARP1KCNH2SIGMAR1PARP2HRH4
SCHEMBL14507 0.82 RIPK1 (0.39) DRD2DRD3
SCHEMBL14058 0.78 KIT (0.38) HRH4CHRNA3ULK1TNKSKIT
SCHEMBL12061562 0.76 KIT (0.39) HRH4CHRNA3ULK1TNKSKIT
SCHEMBL20082480 0.75 SIGMAR1 (0.39) PARP1KCNH2SIGMAR1PARP2KDM4E
SCHEMBL14296 0.69 KIT (0.35) HRH4TNKSKIT
SCHEMBL17277294 0.69 KDM4E (0.30) PARP1KCNH2KDM4EMEN1CACNA1F
SCHEMBL11830521 0.68 SIGMAR1 (0.64) PARP1SIGMAR1MEN1DRD2MAPK1
SCHEMBL13886 0.67 ADORA2A (0.49) HRH4KDM4EMAPTTNKSKIT
SCHEMBL17484520 0.66 PARP1 (0.45) PARP1KCNH2SIGMAR1PARP2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488525-B1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MELINTA THERAPEUTICS INC (US) 2018-04-25 EP disclosed
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME BioVersys AG (CH) 2016-02-04 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
WO-2011047319-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT PARP1 1324/4885KCNH2 3637/4885SIGMAR1 3381/4885
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT PARP1 1324/4885KCNH2 3637/4885SIGMAR1 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.